TERBINAFINE-WT terbinafine (as hydrochloride) 250 mg tablet blister pack

País: Austrália

Língua: inglês

Origem: Department of Health (Therapeutic Goods Administration)

Ingredientes ativos:

terbinafine hydrochloride, Quantity: 281.28 mg

Disponível em:

Medis Pharma Pty Ltd

DCI (Denominação Comum Internacional):

terbinafine hydrochloride

Forma farmacêutica:

Tablet, uncoated

Composição:

Excipient Ingredients: microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate type A; magnesium stearate; hypromellose

Via de administração:

Oral

Unidades em pacote:

42

Tipo de prescrição:

(S4) Prescription Only Medicine

Indicações terapêuticas:

? Treatment in adults of ringworm (tinea corporis, tinea cruris and tinea pedis) due to infection caused by dermatophytes such as Trichophyton (e.g. T. rubrum, T. mentagrophytes, T. verrucosum, T. violaceum), Microsporum canis and Epidermophyton floccosum, where oral therapy is considered appropriate owing to the site, severity or extent of the infection, and the infection is not responsive to topical therapy. ? Onychomycosis in adults (fungal infection of the nail) caused by dermatophyte fungi.

Resumo do produto:

Visual Identification: White to off-white, uncoated biconvex, bevelled edge tablet, engraved 'TER' and '250' with a break line on one side and plain on the other; Container Type: Blister Pack; Container Material: PVC/Al; Container Life Time: 24 Months; Container Temperature: Store below 30 degrees Celsius

Status de autorização:

Licence status A

Data de autorização:

2014-03-20